Somatic diversification of a transgenic TCR to enhance antiviral immunity and prevent immunopathology (P16)

转基因 TCR 的体细胞多样化可增强抗病毒免疫力并预防免疫病理学 (P16)

• 批准号: 275567699
• 金额: --
• 依托单位: Max-Planck-Institut für Immunbiologie und Epigenetik
• 依托单位国家: 德国
• 项目类别: Collaborative Research Centres
• 财政年份: 2015
• 资助国家: 德国
• 起止时间: 2014-12-31 至 2018-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/275567699?language=en
• 关键词: Somatic; diversification; transgenic; TCR; enhance

An impaired pathogen clearance in lymphopenic hosts can lead to chronic activation of the immune system. We intend to investigate the use of RNA-guided DNA endonucleases based on the CRISPR/Cas system as a means to achieve artificial somatic diversification of a transgenic TCR. We will examine whether such somatic diversification of a TCR that is specific for an LCMV-encoded antigenic peptide presented in the context of MHC II results in the emergence of a diverse repertoire of CD4+ and CD8+ T cells, capable of controlling LCMV infection and preventing CD4+ cell-mediated immunopathology.

淋巴细胞减少宿主中病原体清除受损可导致免疫系统的慢性激活。我们打算研究使用基于CRISPR/Cas系统的RNA引导的DNA内切酶作为实现转基因TCR的人工体细胞多样化的手段。我们将研究是否这样的体细胞的TCR，是特定的LCMV编码的抗原肽的背景下提出的MHC II的结果在出现一个多样化的库的CD 4+和CD 8 + T细胞，能够控制LCMV感染和预防CD 4+细胞介导的免疫病理学。